42 related articles for article (PubMed ID: 18312353)
1. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
[TBL] [Abstract][Full Text] [Related]
2. The TRAF2-p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway.
Liang X; Yao J; Cui D; Zheng W; Liu Y; Lou G; Ye B; Shui L; Sun Y; Zhao Y; Zheng M
Cell Death Differ; 2023 Jun; 30(6):1550-1562. PubMed ID: 37081115
[TBL] [Abstract][Full Text] [Related]
3. TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer.
Siegmund D; Wagner J; Wajant H
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011046
[TBL] [Abstract][Full Text] [Related]
4. TRAF2 Knockdown in Nasopharyngeal Carcinoma Induced Cell Cycle Arrest and Enhanced the Sensitivity to Radiotherapy.
Zhu H; Ding W; Wu J; Ma R; Pan Z; Mao X
Biomed Res Int; 2020; 2020():1641340. PubMed ID: 32566659
[TBL] [Abstract][Full Text] [Related]
5. New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.
van Krieken JH
J Hematop; 2008 Jul; 1(1):37-45. PubMed ID: 19669203
[No Abstract] [Full Text] [Related]
6. Primary mediastinal large B-cell lymphoma.
Martelli M; Ferreri AJ; Johnson P
Crit Rev Oncol Hematol; 2008 Dec; 68(3):256-63. PubMed ID: 18774728
[TBL] [Abstract][Full Text] [Related]
7. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
8. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
12. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
13. [Primary breast lymphoma--a report of 27 cases with literature review].
Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]